innerbuddies gut microbiome testing

TMAO and the Gut Microbiome: How It Shapes Cardiometabolic Risk

TMAO (trimethylamine N-oxide) has become a key biomarker—and a growing mechanistic link—between the gut microbiome and cardiometabolic health. Unlike many risk factors that reflect what happens after digestion, TMAO is strongly shaped by microbial metabolism: certain gut bacteria convert dietary nutrients such as choline, phosphatidylcholine, and L-carnitine into trimethylamine (TMA), which the liver then oxidizes into TMAO.

Because different microbial communities produce different amounts of TMA, TMAO levels can vary widely from person to person and even change in response to diet, medication, and lifestyle. When microbial activity shifts toward pathways that generate more TMA, TMAO may influence cardiometabolic risk through multiple routes—supporting atherosclerosis-related processes, altering cholesterol and bile acid signaling, affecting inflammation, and interacting with vascular and metabolic function. In short, the gut ecosystem can act as an “upstream regulator” of TMAO biology.

The practical takeaway is that gut-focused strategies may help modulate TMAO production and cardiometabolic risk. Approaches like improving dietary fiber and polyphenol intake to encourage beneficial microbes, limiting excess reliance on high-TMAO-promoting dietary patterns, and understanding how antibiotics or metabolic medications can reshape the microbiome all matter. By targeting the microbiome-TMAO axis, you can better support heart health—moving beyond traditional risk assessment to a more biology-driven, gut-informed perspective.

Test Your Gut Microbiome for TMAO Risk Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

TMAO-related cardiometabolic discussions

TMAO is a gut microbiome–derived metabolite linked to cardiometabolic risk. Dietary nutrients such as choline, L-carnitine, and phosphatidylcholine are converted by gut microbes into trimethylamine (TMA), which the liver oxidizes to TMAO via FMO3, forming a gut–liver–heart axis that influences endothelial function, vascular inflammation, bile acid metabolism, cholesterol handling, and insulin resistance. In this view, TMAO reflects functional gut-driven signaling rather than a single dietary marker, with microbial ecology and barrier integrity shaping how these signals manifest.

Practical implications center on testing and dietary/microbiome strategies. Microbiome profiling helps explain why similar diets yield different TMAO levels, since there is no universal cutoff for elevated TMAO. Diets emphasizing fiber-rich, plant-forward foods may support beneficial taxa and short-chain fatty acid production, while moderating high-TMAO precursor foods (certain red meats and choline/carnitine sources) may reduce microbial TMA production. Emerging microbiome-directed interventions and pharmacologic approaches are under study to modulate TMAO formation and downstream cardiometabolic risk.

How InnerBuddies helps: it connects TMAO to upstream gut drivers, highlighting patterns of TMA production and related bile acid handling, cholesterol transport, endothelial function, and inflammatory signaling. This enables personalized diet and gut-targeted strategies, helping clinicians and individuals identify baseline microbiome features that influence TMAO and guide targeted use of prebiotics, probiotics, or other microbiome-directed approaches to reduce cardiometabolic risk via the gut–liver axis.

  • TMAO levels are driven by gut microbial capacity to convert dietary precursors into TMA; elevated TMA-producing taxa (e.g., Clostridium cluster IV, Escherichia/Shigella with CutC/CntA, Desulfovibrio, Bacteroides thetaiotaomicron, Anaerococcus, Peptostreptococcus, Methanobrevibacter smithii) are key contributors to higher circulating TMAO.
  • Beneficial, fiber-fermenting taxa (Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, Anaerostipes, Bifidobacterium spp., Akkermansia muciniphila, Ruminococcus bromii) are relatively low in individuals with high TMAO and support gut barrier integrity and short-chain fatty acid production that may counterbalance TMAO risk.
  • Choline/L-carnitine/phosphatidylcholine metabolism to TMA is the main microbial pathway; the presence of TMA lyase genes (CutC, CntA) in taxa like Clostridium and certain Proteobacteria links microbiome composition to TMAO formation.
  • The liver converts TMA to TMAO via FMO3; host hepatic metabolism interacts with microbiome-driven TMA production to determine net TMAO risk.
  • Gut–liver–heart axis: TMAO-related signals involve bile acid ecology and cholesterol transport; shifts toward TMA-producing microbiota can perturb bile acid metabolism and lipid handling through microbial communities.
  • Dietary and microbiome-targeted strategies (high-fiber, plant-forward diets; moderated intake of high-TMAO precursors; prebiotics/probiotics) aim to tilt the microbiome away from TMA production and toward SCFA-producing, barrier-supporting taxa.
  • Microbiome testing can guide personalized interventions by identifying baseline patterns indicating higher TMA production risk and showing which taxa to target with diet or microbiome-directed therapies.
Test Your Gut Microbiome for TMAO Risk Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Cardiovascular risk-related topics

TMAO (trimethylamine N-oxide) is a gut microbiome–derived metabolite that has gained attention for its connection to cardiometabolic risk. Dietary nutrients such as choline, L-carnitine, and phosphatidylcholine are metabolized by specific gut microbes into trimethylamine (TMA). The liver then converts TMA into TMAO via flavin-containing monooxygenases (notably FMO3). Because TMA production depends on microbial composition and metabolic activity, TMAO can be viewed as a functional “readout” of gut-driven metabolic signaling rather than just a single dietary marker.

Research links higher circulating TMAO to pathways relevant to cardiovascular disease and metabolic health, including altered bile acid metabolism, impaired cholesterol handling, increased platelet hyperreactivity, endothelial dysfunction, and promotion of vascular inflammation. TMAO has also been associated with insulin resistance and adverse metabolic phenotypes, potentially through effects on gut barrier integrity, microbial ecology, and signaling networks that influence glucose and lipid metabolism. Mechanistically, the gut–liver–heart axis is central: microbial metabolism generates TMA, hepatic processing and downstream signaling shape host physiology, and resulting metabolic and inflammatory changes can contribute to cardiometabolic risk.

From a practical standpoint, strategies that influence gut ecology and microbial TMA production may help modulate TMAO-related risk. Diets emphasizing fiber-rich, minimally processed foods (which support beneficial taxa and short-chain fatty acid production) may indirectly reduce TMAO precursors’ microbial fermentation. Adjusting intake of high-TMAO precursor foods (notably some red meats and certain high-carnitine or choline sources) while prioritizing plant-forward protein sources can also be considered, particularly within an overall heart-healthy dietary pattern. Therapeutic approaches under study include targeting microbial metabolism via prebiotics/probiotics, diet-driven microbiome modulation, and pharmacologic interventions that reduce precursor availability or TMAO formation pathways—highlighting how personalized gut microbiome management may be an emerging lever for cardiovascular and cardiometabolic support.

  • Elevated blood levels of TMAO (often detected via lab testing before symptoms)
  • Chest discomfort or reduced exercise tolerance (cardiovascular strain)
  • High blood pressure
  • Insulin resistance or rising blood glucose levels
  • Increased LDL cholesterol and/or dyslipidemia
  • Abdominal bloating or altered bowel habits (gut microbiome dysbiosis)
Test Your Gut Microbiome for TMAO Risk Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

TMAO-related cardiometabolic discussions

This discussion on TMAO-related cardiometabolic risk is most relevant for people trying to understand why cardiovascular and metabolic markers may be trending upward despite “standard” heart-healthy efforts—especially when labs show elevated TMAO before other symptoms appear. It can be particularly useful for individuals with cardiometabolic risk factors such as high blood pressure, worsening cholesterol patterns (e.g., higher LDL or dyslipidemia), or early metabolic disruption like insulin resistance and rising blood glucose. Because TMAO is a gut microbiome–driven metabolite (a functional readout of microbial processing of choline/L-carnitine/phosphatidylcholine), it may resonate with those who want a gut-centered explanation for upstream drivers of heart and metabolic health.

It’s also relevant for people who notice gut and systemic symptoms at the same time—such as abdominal bloating, altered bowel habits, or signs of gut barrier dysregulation—along with reduced exercise tolerance, chest discomfort, or vascular strain. In these contexts, the gut–liver–heart axis is especially pertinent: gut microbes generate TMA precursors from specific dietary nutrients, the liver converts TMA to TMAO (notably via FMO3), and the downstream effects may involve bile acid metabolism changes, impaired cholesterol handling, endothelial dysfunction, and inflammation that can worsen cardiometabolic physiology.

Finally, this topic is valuable for those who are interested in actionable, personalized strategies that target gut ecology rather than only downstream symptoms—such as optimizing diet composition for microbiome function. It may apply to individuals who regularly consume foods that provide TMAO precursors (certain red meats, and some higher-choline or high-carnitine dietary sources) and want to shift toward fiber-rich, minimally processed, plant-forward patterns or adjust protein sources. It can also be relevant for patients and clinicians exploring prebiotic/probiotic approaches, diet-driven microbiome modulation, or emerging pharmacologic concepts aimed at reducing precursor availability and/or TMAO formation pathways.

Population-level prevalence of “TMAO-related” cardiometabolic risk is typically described by the proportion of people with elevated circulating trimethylamine N-oxide (TMAO), because elevated TMAO is often detected on blood testing before overt symptoms. However, there is no single universal cutoff or standardized assay used across studies, so reported prevalence varies widely by cohort, geography, diet pattern, and lab method—making direct “% of the population” estimates inconsistent.

That said, TMAO elevation is common enough to be repeatedly observed in large observational studies, and higher TMAO levels are frequently found in people who also show cardiometabolic abnormalities. In practice, many adults with related conditions—such as insulin resistance, dyslipidemia (including higher LDL cholesterol), hypertension, and early cardiovascular disease risk—also exhibit a higher frequency of elevated TMAO, suggesting TMAO dysregulation tracks with broad metabolic dysfunction rather than a rare disorder. Reported rates of these cardiometabolic conditions themselves are high (e.g., insulin resistance is widespread in adults globally; hypertension affects a large fraction of adults), and TMAO tends to be overrepresented in these groups.

The most commonly reported “symptom patterns” for TMAO-related risk (often reflecting upstream gut–liver changes) are therefore usually not specific standalone symptoms but concurrent clinical features—chest discomfort or reduced exercise tolerance, higher blood pressure, insulin resistance/rising glucose, dyslipidemia, and GI complaints such as bloating or altered bowel habits. Because elevated TMAO can precede these findings and because gut microbiome–driven metabolic phenotypes are strongly influenced by diet (red meat and certain choline/carnitine sources versus fiber-rich plant patterns), the practical prevalence is best viewed as frequent among adults with cardiometabolic risk factors: in other words, a substantial segment of the population may have TMAO levels associated with increased cardiometabolic risk, even when true prevalence depends on the study-specific measurement thresholds.

Test Your Gut Microbiome for TMAO Risk Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

TMAO & the Gut Microbiome: How Cardiometabolic Risk Is Shaped

TMAO (trimethylamine N-oxide) is tightly linked to the gut microbiome because it begins with microbial metabolism of dietary nutrients such as choline, L-carnitine, and phosphatidylcholine into trimethylamine (TMA). Different gut microbial communities vary in their capacity to produce TMA, making circulating TMAO a functional readout of gut-driven metabolic activity rather than just a straightforward dietary marker. After TMA is produced, the liver converts it to TMA via flavin-containing monooxygenases (especially FMO3), creating a gut–liver axis that can influence cardiometabolic physiology.

Higher TMAO levels have been associated with several cardiometabolic pathways that connect back to gut microbial function, including altered bile acid metabolism, impaired cholesterol handling, endothelial dysfunction, vascular inflammation, and increased platelet hyperreactivity. These effects may help explain why TMAO is often observed alongside adverse metabolic phenotypes, such as insulin resistance and dysregulated glucose and lipid metabolism. In addition, gut microbial ecology and integrity of the intestinal barrier may play roles in how microbial metabolites shape systemic signaling networks that affect cardiometabolic risk.

Practically, symptoms or clinical patterns that co-occur with elevated TMAO—such as reduced exercise tolerance or chest discomfort (reflecting cardiovascular strain), higher blood pressure, rising blood glucose/insulin resistance, dyslipidemia, and GI changes like bloating or altered bowel habits—often align with microbiome dysregulation and altered fermentation patterns. Diets that increase fiber and minimally processed, plant-forward foods can promote beneficial taxa and short-chain fatty acid production, which may indirectly reduce TMAO precursor fermentation. Conversely, higher intakes of certain high-TMAO-precursor foods (notably some red meats and choline- or carnitine-rich sources) may increase microbial TMA production. Emerging interventions such as prebiotics/probiotics and microbiome-targeted pharmacologic strategies aim to modulate these gut-driven steps in the TMAO pathway, offering a personalized gut-centric lever for cardiometabolic support.

Test Your Gut Microbiome for TMAO Risk Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and TMAO-related cardiometabolic discussions

  • Gut microbial conversion of dietary precursors (choline, L-carnitine, phosphatidylcholine) into TMA, with inter-individual differences in microbial taxa determining circulating TMAO levels
  • Gut–liver axis via hepatic flavin-containing monooxygenase 3 (FMO3), which oxidizes TMA to TMAO and links microbial metabolism to systemic cardiometabolic signaling
  • Altered bile acid metabolism and enterohepatic signaling, where TMAO-associated changes can shift cholesterol handling, lipid metabolism, and metabolic homeostasis
  • Impaired cholesterol transport and reverse cholesterol transport (e.g., effects on macrophage cholesterol efflux and lipoprotein pathways), contributing to atherogenic risk
  • Endothelial dysfunction and vascular inflammation, potentially mediated by TMAO-driven changes in oxidative stress and inflammatory signaling
  • Pro-thrombotic effects including increased platelet hyperreactivity, which can elevate cardiometabolic event risk
  • Intestinal barrier disruption and gut dysbiosis, enabling inflammatory signaling (e.g., endotoxin-related pathways) that amplifies cardiometabolic dysfunction alongside microbiome-derived metabolites

TMAO is tightly connected to gut microbial metabolism. Dietary nutrients such as choline, L-carnitine, and phosphatidylcholine can be converted by specific gut bacteria into trimethylamine (TMA). Because different individuals harbor gut communities with different “TMA-producing” capabilities, circulating TMAO levels function as a readout of gut-driven metabolic activity rather than simply reflecting what someone ate.

Once TMA is absorbed, the liver oxidizes it to TMAO—largely via flavin-containing monooxygenase 3 (FMO3)—forming a gut–liver axis that can influence cardiometabolic physiology. TMAO is also linked to altered bile acid metabolism and enterohepatic signaling, which can shift cholesterol handling, lipid homeostasis, and metabolic regulation. In turn, these changes may impair reverse cholesterol transport (including effects relevant to macrophage cholesterol efflux), promoting a more atherogenic cardiometabolic profile.

Beyond lipid and bile acid pathways, TMAO-associated signals are connected to vascular and inflammatory dysfunction. Evidence suggests effects on endothelial function, oxidative stress, and vascular inflammation, along with pro-thrombotic biology such as increased platelet hyperreactivity that can raise risk for adverse cardiovascular events. Meanwhile, gut dysbiosis and intestinal barrier disruption can amplify systemic inflammation (e.g., via endotoxin-related signaling), creating a reinforcing loop where microbial metabolites like TMAO and inflammatory signals jointly contribute to insulin resistance, dysregulated glucose/lipid metabolism, and broader cardiometabolic risk.

Test Your Gut Microbiome for TMAO Risk Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In people with higher TMAO, gut microbiome function often shifts toward a community enriched for organisms capable of converting dietary TMAO precursors—especially choline, L-carnitine, and phosphatidylcholine—into trimethylamine (TMA). Because microbial “TMA-producing” capacity varies by individual, this pattern can look like a dysbiotic fermentation profile where more of the available substrate is processed into TMA before absorption. Alongside this, overall ecological imbalance (often reflected as reduced beneficial commensal diversity) may favor taxa that support these metabolic routes rather than fiber-fermenting pathways, which can otherwise generate short-chain fatty acids (SCFAs) that support gut barrier function and metabolic homeostasis.

A second common pattern is disrupted gut–liver signaling driven by downstream metabolism of TMAO. Changes in microbial activity can alter bile acid composition and enterohepatic signaling, which in turn affects cholesterol handling and lipid regulation. Microbial states that promote higher TMA/TMAO flux may coincide with altered bile salt hydrolase and bile acid-transforming communities, creating a feedback loop where bile acid changes further shape the gut ecosystem. The result is a gut ecology less effective at maintaining balanced lipid metabolism, with systemic spillover that aligns with cardiometabolic phenotypes like dyslipidemia and worsening insulin sensitivity.

Finally, elevated TMAO frequently co-occurs with microbiome-associated barrier dysfunction and a pro-inflammatory signaling milieu. When the intestinal barrier is less intact—often due to dysbiosis that reduces protective SCFAs—microbial metabolites and inflammatory triggers can access systemic circulation more easily, amplifying vascular inflammation and endothelial stress. This environment can reinforce metabolic dysregulation (including insulin resistance) through inflammatory pathways, while TMAO itself is linked to vascular and pro-thrombotic biology such as platelet hyperreactivity. Together, these patterns describe a gut microbial ecosystem where enhanced TMA-producing metabolism, altered bile acid ecology, and impaired barrier-associated signaling collectively contribute to cardiometabolic risk.


Low beneficial taxa

  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Eubacterium rectale
  • Anaerostipes spp.
  • Bifidobacterium spp.
  • Akkermansia muciniphila
  • Ruminococcus bromii


Elevated / overrepresented taxa

  • Clostridium spp. (e.g., Clostridium cluster IV)
  • CutC/CntA-possessing Proteobacteria (e.g., Escherichia/Shigella)
  • Desulfovibrio spp.
  • Bacteroides spp. (B. thetaiotaomicron and related bile/sterol–modulating members)
  • Anaerococcus spp.
  • Peptostreptococcus spp.
  • Methanobrevibacter smithii


Functional pathways involved

  • Choline/TMA (trimethylamine) production from dietary precursors (choline, phosphatidylcholine, L-carnitine) via microbial TMA lyase and related transferase pathways
  • TMAO generation and trimethylamine–to–TMAO oxidative metabolism (including microbial- and host-linked flux contributing to circulating TMAO)
  • Bile acid transformation and bile salt hydrolase (BSH)-associated bile acid deconjugation/reconjugation pathways
  • Sterol/secondary bile acid metabolism (bile/sterol–modulating gut microbial pathways that reshape cholesterol and lipid handling)
  • Gut barrier integrity maintenance via short-chain fatty acid (SCFA) biosynthesis pathways (e.g., butyrate-producing fermentation routes)
  • Microbial sulfur metabolism and hydrogen sulfide (H2S)–linked pathways (e.g., Desulfovibrio-associated sulfur reduction) influencing inflammation signaling
  • Gut–liver axis signaling modulation through enterohepatic circulation effects driven by bile acid–microbiome feedback loops
  • Pro-inflammatory metabolite and endotoxin-associated signaling (lipopolysaccharide/LPS-related and proteolytic fermentation-derived inflammatory stimuli) contributing to cardiometabolic inflammation


Diversity note

Higher circulating TMAO is often linked to a gut ecosystem with reduced microbial diversity and a shift in community function away from fiber-centric fermentation. When diversity and “protective” commensals are diminished, the gut tends to favor taxa and metabolic pathways that more efficiently process dietary TMAO precursors—particularly choline, L-carnitine, and phosphatidylcholine—into trimethylamine (TMA). This functional tilt can be viewed as a more dysbiotic fermentation pattern, where available substrate is preferentially routed toward TMA/TMAO production rather than toward short-chain fatty acid (SCFA) generation that supports barrier health and metabolic regulation.

In this context, the microbiome’s altered balance also affects gut–liver signaling. Communities that expand around TMA-producing activity frequently coincide with bile acid–transforming changes, including shifts in bile acid composition that further reshape the gut environment. As diversity declines, the resulting ecological feedback loop can stabilize microbial states that are less effective at maintaining balanced lipid handling and enterohepatic signaling, which is often observed alongside cardiometabolic phenotypes associated with elevated TMAO.

Finally, lower diversity commonly tracks with weaker intestinal barrier integrity and a more pro-inflammatory signaling milieu. When SCFA-producing organisms are reduced, the gut barrier may become more permeable, allowing microbial metabolites and immune-stimulating signals to exert stronger systemic effects. This combination—diminished diversity, reduced barrier-supportive fermentation, and enhanced TMAO-related metabolic capacity—creates conditions that can amplify vascular inflammation and endothelial stress, reinforcing the association between elevated TMAO and cardiometabolic risk.


Test Your Gut Microbiome for TMAO Risk Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    Generic “gut health” advice often fails for TMAO-related cardiometabolic risk because TMAO is not merely a marker of diet—it is a functional readout of an individual’s gut–microbial capacity to convert specific dietary precursors (choline, L-carnitine, phosphatidylcholine) into TMA, followed by host conversion to TMAO in the liver (notably via FMO3). Two people can consume similar “healthy” diets but harbor different microbial communities and enzymatic capabilities, so the same broad recommendation (e.g., simply cutting meat or taking a general probiotic) may not meaningfully reduce the microbial TMA-forming flux in the first place.

    Likewise, generic solutions overlook the fact that TMAO-linked risk often co-tracks with bile acid remodeling and gut–liver signaling. Microbial taxa and bile acid–transforming pathways vary widely between individuals; in some, a TMAO-inclined ecosystem corresponds to altered bile acid composition that disrupts cholesterol handling and metabolic signaling. Without addressing that specific gut–bile acid ecology—rather than only focusing on “fiber more” or “eat better” in a non-personalized way—interventions may not break the feedback loop between bile acid changes and microbial community shifts that sustain dyslipidemia and worsening insulin sensitivity.

    Finally, broad interventions tend to miss the barrier-and-inflammation dimension that frequently accompanies elevated TMAO. When dysbiosis reduces SCFA-producing commensals, intestinal barrier integrity can decline, allowing microbial products and pro-inflammatory signals to reach systemic circulation more readily—amplifying endothelial stress, vascular inflammation, and platelet hyperreactivity. A generic plan that does not evaluate (or support) barrier-associated functions, microbial diversity, and the specific metabolic outputs of the microbiome may therefore produce inconsistent results, because the key drivers of cardiometabolic risk in this indication are ecosystem-level behaviors, not isolated supplements or generic dietary changes.

  • Common mistakes

    • Treating TMAO as a generic “diet marker” and not as a functional readout of an individual’s gut microbial capacity to convert choline/L-carnitine/phosphatidylcholine into TMA (then host-converted to TMAO via FMO3).
    • Relying on broad advice like “eat healthier,” “cut meat,” or “add more fiber” without accounting for inter-individual differences in microbial enzyme/function (i.e., whether a person’s microbiome can actually generate high TMA/TMAO flux).
    • Using generic probiotics without targeting TMA-producing metabolic routes or checking whether the specific strains can meaningfully shift bile acid/TMA ecology (and sometimes the wrong strains can be neutral or ineffective for this mechanism).
    • Ignoring the gut–liver/bile acid feedback loop—focusing only on TMAO reduction while not addressing microbial bile acid remodeling pathways (e.g., bile salt hydrolase and bile acid–transforming communities) that can sustain dyslipidemia and insulin resistance.
    • Assuming all fiber is equal—promoting fiber broadly but missing whether fiber interventions actually restore SCFA-producing commensals and barrier-supporting ecology needed to counter inflammation associated with elevated TMAO.
    • Overlooking intestinal barrier and inflammatory context—failing to support barrier integrity (SCFAs, ecological diversity, anti-inflammatory signaling) when dysbiosis is already increasing permeability and systemic immune/vascular activation.
    • Not considering timing/dosing and precursor exposure patterns—recommending meal- or day-level changes without addressing how frequently and how much TMAO precursors (choline- and carnitine-rich foods) are delivered to the gut for microbial conversion.
    • Failing to individualize based on cardiometabolic phenotype co-tracking—treating everyone the same despite elevated TMAO often coinciding with dyslipidemia, worsening insulin sensitivity, and pro-thrombotic biology.

What to do

  • General support strategies

    Supporting TMAO-related cardiometabolic health centers on modulating the gut microbial steps that generate TMA and influence downstream liver conversion to TMAO. Because circulating TMAO reflects gut-driven metabolism of dietary precursors like choline, L-carnitine, and phosphatidylcholine, strategies that improve microbial ecology—while reducing fermentation pathways that favor TMA production—may help lower cardiometabolic risk signals linked to TMAO. This includes fostering an intestinal environment with better barrier integrity and more metabolically diverse communities, which can reduce the systemic impact of gut-derived signals on inflammation, endothelial function, and metabolic regulation.

    Diet is the most practical lever. Emphasizing a fiber-rich, minimally processed, plant-forward pattern can support beneficial taxa and increase short-chain fatty acid production, which is associated with healthier bile acid signaling and improved cholesterol handling. At the same time, reducing reliance on high-risk TMAO precursor sources—particularly diets heavy in certain red meats and foods concentrated in choline- or carnitine-related substrates—may decrease the availability of compounds that microbes convert into TMA. Tailoring food choices to favor overall cardiometabolic quality (e.g., higher vegetables, legumes, whole grains, and unsaturated fats) helps steer the gut toward fermentation outputs that are generally less pro-inflammatory.

    Emerging adjuncts such as prebiotics, probiotics, and microbiome-targeted approaches may further influence TMAO dynamics by shifting microbial composition and functional capacity. Prebiotics can “feed” beneficial organisms that compete with or suppress TMA-producing pathways, while selected probiotics may influence metabolite production and gut barrier function. In addition, personalized interventions based on gut-centric biomarkers and dietary responsiveness are increasingly relevant, since different individuals harbor distinct microbial communities and therefore generate TMAO at different rates. Combined with lifestyle measures that improve insulin sensitivity and vascular health, these microbiome-targeted strategies offer a coherent, gut-first framework for addressing TMAO-associated cardiometabolic concerns.

  • Lifestyle recommendations

    • Increase dietary fiber with a plant-forward pattern (vegetables, legumes, whole grains, nuts) to support beneficial gut ecology and reduce TMAO precursor fermentation.
    • Limit intake of foods high in TMAO precursors (especially red/processed meats and high choline- or carnitine-rich foods) and choose fish in smaller/less frequent portions depending on your risk profile.
    • Prioritize whole-food meal prep and minimize ultra-processed foods to reduce dysbiosis-promoting dietary inputs.
    • Consider evidence-based microbiome support strategies such as prebiotics and/or probiotics (e.g., fiber-rich foods plus fermented foods) tailored to tolerance and goals.
    • Maintain regular physical activity and healthy body weight, as improved metabolic health can counteract cardiometabolic pathways linked with elevated TMAO.
    • If you notice GI changes (bloating, altered bowel habits) alongside cardiometabolic symptoms, address gut health early with dietary adjustments and seek medical guidance for targeted evaluation.

  • Nutrition recommendations

    • Prioritize a fiber-rich, plant-forward diet (aim for a variety of legumes, whole grains, vegetables, berries, and nuts) to support beneficial gut taxa and reduce flux toward TMA/TMAO precursor fermentation.
    • Limit high-TMAO-precursor foods—especially red and processed meats—by reducing portion size and frequency (e.g., swap toward fish, poultry, or plant-based protein more often when appropriate).
    • Reduce intake of choline- and carnitine-heavy dietary sources if TMAO is elevated (e.g., avoid high-dose supplements like carnitine; moderate egg intake depending on individual response).
    • Choose minimally processed foods and emphasize prebiotic substrates (e.g., inulin/chicory root, garlic, onions, leeks, asparagus, oats) to foster microbial communities associated with healthier metabolite profiles.
    • Increase short-chain-fatty-acid–supporting foods (beans/lentils, oats, resistant starch sources like cooled cooked potatoes/rice) to strengthen gut barrier function and shift microbial metabolism away from TMA production.
    • Use probiotic/prebiotic–rich strategies when tolerated (foods like yogurt/kefir/fermented vegetables or targeted prebiotic/probiotic combinations) to improve microbiome ecology, while monitoring individual tolerance and clinical response.
    • If GI symptoms coexist (bloating, altered bowel habits), personalize fiber type and gradually increase intake; consider omega-3–rich fish or ALA sources as dietary supports for cardiometabolic risk while continuing microbiome-focused changes.

  • Supplement considerations

    Because TMAO is generated through a gut–microbial conversion of dietary precursors (such as choline, L-carnitine, and phosphatidylcholine) into TMA, supplement strategies that target the microbiome ecology can be more relevant than simply trying to “lower TMAO” directly. Approaches that support a more diverse, fiber-adapted microbial community (e.g., prebiotic fibers that increase beneficial fermentation patterns and short-chain fatty acid production) may reduce the relative availability of substrates or pathways that favor TMA formation. In practice, combining prebiotics with carefully selected probiotics can be considered to shift microbial metabolism away from TMA production, though effects can be strain-specific and may depend on baseline diet and existing microbiome composition.

    Given that the liver enzyme FMO3 converts TMA to TMAO, supplement considerations should also account for systemic metabolism and endothelial/platelet pathways linked to cardiometabolic risk. Compounds with anti-inflammatory or endothelial-supportive potential may complement gut-targeted interventions, especially for people showing cardiometabolic co-signals such as insulin resistance, dyslipidemia, or vascular dysfunction. However, it’s important to avoid assuming one-size-fits-all benefits: supplement responsiveness is influenced by gut barrier integrity, bile acid handling, and the degree of dysbiosis, so monitoring tolerability (e.g., GI changes like bloating) and timing around dietary patterns can matter.

    Finally, supplement selection should be integrated with dietary context. If someone is using supplements while consuming high levels of TMAO-precursor foods, the gut may still generate abundant TMA for conversion to TMAO, potentially blunting microbiome-targeted benefits. For risk-focused personalization, a pragmatic route is to prioritize minimally processed, plant-forward nutrition to support protective taxa, then consider targeted pre/probiotic or synbiotic formulations as adjuncts—while avoiding unnecessary high-choline or carnitine supplementation if TMAO is a concern. Where possible, clinicians may use metabolic labs and symptom patterns to gauge whether gut-centered interventions are translating into improved cardiometabolic markers.

  • Retesting / monitoring note

    Retesting for TMAO is most informative when it’s timed to reflect changes in gut-driven metabolism rather than day-to-day variation. Because circulating TMAO depends on microbial generation of trimethylamine (TMA) from dietary precursors (e.g., choline, L-carnitine, phosphatidylcholine) and subsequent hepatic conversion to TMA (notably via FMO3), clinicians often consider repeat testing after a meaningful interval following diet and lifestyle adjustments that are likely to shift the gut microbiome’s fermentative capacity. In practice, retesting is commonly planned after several weeks to allow microbial communities and bile acid/cholesterol handling to adapt—especially when recommendations include increasing fiber and minimally processed plant-forward foods or reducing higher-precursor animal-based intake.

    To improve interpretability, retesting should be performed with attention to pre-analytical and contextual factors. Ideally, blood is collected under consistent conditions (e.g., fasting status, avoidance of meals high in choline/carnitine shortly beforehand) and with documentation of recent dietary patterns, GI symptoms, medication changes, and cardiovascular/metabolic variables such as glucose control, lipid trends, and blood pressure. If the goal is to evaluate a microbiome-targeted intervention (prebiotic/probiotic strategies or other gut-directed approaches), retesting around the same phase of the intervention each time helps distinguish true biological change from variability.

    Finally, because TMAO is one functional readout among many cardiometabolic pathways, retesting is most useful when paired with complementary markers and a clear decision threshold. Many clinicians track TMAO alongside lipid parameters, markers of insulin resistance, and inflammation/endothelial function measures, then reassess within the same timeframe as the metabolic endpoints. If TMAO remains elevated despite adherence, it can prompt refinement of the gut-focused plan—such as more aggressive fiber/plant-diversity optimization, evaluation of adherence and gut barrier health (e.g., persistent bloating or altered bowel habits), and consideration of personalized dietary sources of TMAO precursors—before repeating follow-up measurements.

The importance of gut microbiome testing

  • Why testing matters

    Gut microbiome testing matters for TMAO-related cardiometabolic discussions because TMAO is not just a passive dietary marker—it’s a functional output of gut microbial metabolism. Dietary precursors such as choline, L-carnitine, and phosphatidylcholine are converted by specific gut microbes into trimethylamine (TMA), and then the liver converts TMA into TMAO via enzymes like FMO3. Since different microbiome compositions have different capacities to produce TMA, measuring or profiling the gut ecosystem can help explain why people with similar diets can show very different circulating TMAO levels.

    Testing also adds context around the upstream drivers of TMAO biology, including microbial ecology and intestinal barrier integrity. Microbiome dysregulation can shift fermentation patterns toward higher TMA-producing pathways, while compromised gut function can alter host exposure to microbial metabolites that influence bile acid handling, cholesterol transport, endothelial function, vascular inflammation, and platelet reactivity. In other words, microbiome data can help connect elevated TMAO to broader gut-derived metabolic signaling that overlaps with insulin resistance and dysregulated lipid and glucose metabolism.

    From a practical standpoint, microbiome testing supports more personalized interventions aimed at reducing cardiometabolic risk via the gut–liver axis. By identifying baseline community patterns associated with higher TMA production and/or lower fiber-fermenting capacity, clinicians can better tailor dietary changes (for example, increasing plant-forward, high-fiber intake while moderating high TMAO-precursor foods) and consider microbiome-targeted strategies such as prebiotics, probiotics, or other microbiome-directed approaches. This makes the testing results actionable for targeting the microbial step that generates TMAO, rather than only reacting to the biomarker after it rises.

  • How InnerBuddies helps

    InnerBuddies helps make TMAO-related cardiometabolic risk more actionable by connecting the biomarker to its upstream gut drivers. Because circulating TMAO reflects gut microbial capacity to generate trimethylamine (TMA) from dietary precursors like choline, L-carnitine, and phosphatidylcholine—and then liver conversion via FMO3—microbiome composition and fermentation capacity matter. InnerBuddies can provide insight into the gut ecosystem patterns associated with higher or lower TMA-producing activity, helping explain why people eating similar diets can show different TMAO levels.

    In addition to upstream TMA generation, TMAO biology overlaps with bile acid handling, cholesterol transport, endothelial function, vascular inflammation, and even platelet hyperreactivity—processes strongly influenced by microbial metabolism and gut barrier integrity. InnerBuddies can support a broader interpretation of your gut environment by highlighting community-level features tied to gut resilience and metabolic signaling. That context helps clinicians and individuals connect elevated TMAO (or related cardiometabolic patterns such as insulin resistance, dyslipidemia, and GI changes) to modifiable microbiome functions rather than treating TMAO as an isolated lab value.

    With microbiome-derived context, InnerBuddies also supports personalization of diet and gut-targeted interventions. By identifying baseline patterns that suggest lower fiber-fermenting potential or less favorable fermentation profiles, you can tailor plant-forward, high-fiber dietary strategies designed to shift microbial activity away from excessive TMA production. Conversely, it can guide moderation of high TMAO-precursor foods that may promote TMA-generating pathways for certain individuals, and it can inform targeted use of prebiotics/probiotics or other microbiome-directed approaches to reduce cardiometabolic risk via the gut–liver axis.

Medical Evidence

  • Scientific evidence level

    2 [weak / emerging but inconsistent]

  • Clinical relevance note

    At present, the strongest clinically relevant statement is pathway-level: gut microbial metabolism plausibly contributes to circulating TMAO, and TMAO is associated with cardiometabolic risk. However, this does not yet establish that measuring the gut microbiome provides incremental, validated clinical value for diagnosing, preventing, or treating cardiometabolic disease. Many microbiome findings tied to TMAO are not yet robustly reproducible across studies, and they often lack external validation in independent cohorts and standardized assay/analysis frameworks.

    Microbiome-targeted intervention evidence is also not yet actionable for routine care. Dietary interventions that reduce TMAO precursors (and thereby may lower TMAO) are more plausible than “microbiome modulation” per se, but even then, trial outcomes are typically surrogate (TMAO changes) rather than clinically meaningful endpoints, and duration may be too short to capture event prevention. Until larger, well-controlled randomized trials demonstrate that microbiome modulation changes TMAO and leads to improved cardiometabolic outcomes—and until microbiome-based biomarkers show reproducible performance and added value over existing measures—the current evidence supports hypothesis generation and mechanistic plausibility more than clinical decision-making.

Title Journal Year Link
Trimethylamine N-oxide (TMAO) is associated with incident cardiovascular events in patients with chronic kidney disease JAMA Cardiology 2017 View →
TMAO: A metabolite link between the gut microbiota and cardiovascular disease Cell Metabolism 2014 View →
Trimethylamine N-oxide and mortality in atherosclerotic cardiovascular disease: a prospective cohort study The Journal of the American College of Cardiology 2013 View →
Gut microbiota metabolism of L-carnitine in fat-fed subjects produces TMAO Science 2011 View →
Intestinal microbial metabolism of phosphatidylcholine promotes atherosclerosis Nature Medicine 2011 View →

Frequently Asked Questions

    ¿Qué es TMAO y por qué se asocia con el riesgo cardiometabólico?
    TMAO es un metabolito derivado del microbioma intestinal producido a partir de nutrientes como la colina y el L-carnitina; el hígado lo oxida a TMAO principalmente mediante FMO3. Niveles más altos se asocian con vías relevantes para enfermedades cardiovasculares y salud metabólica; refleja la actividad microbiana, no solo un marcador dietético.
    ¿Cómo se produce TMAO en el cuerpo?
    Las bacterias intestinales transforman precursores como la colina y la L-carnitina en trimetilamina (TMA); el hígado la oxida a TMAO mediante FMO3; existe un eje intestino–hígado.
    ¿Los niveles altos de TMAO son una causa o solo un marcador?
    Se asocian con vías metabólicas y cardiovasculares; son un resultado funcional de la señalización intestinal; no prueban causalidad; muchos factores influyen.
    ¿Qué alimentos debo limitar o enfatizar para influir en los niveles de TMAO?
    Limitar alimentos con alto contenido de precursores de TMAO (algunas carnes rojas, fuentes de colina/carnitina); enfatizar alimentos ricos en fibra y de base vegetal; en general, un patrón saludable para el corazón.
    ¿La prueba del microbioma ayuda con el riesgo de TMAO?
    Puede aportar contexto sobre la capacidad de producción de TMA y la ecología intestinal para orientar estrategias dietéticas y microbioma dirigidas; no es un diagnóstico por sí sola.
    ¿Qué intervenciones existen para reducir el riesgo de TMAO?
    Cambios en la dieta, prebióticos/probióticos y otras estrategias orientadas al microbioma; las estrategias farmacológicas están en estudio; se optimizan de forma personalizada.
    ¿Cómo se relaciona TMAO con la resistencia a la insulina y la dislipidemia?
    TMAO está vinculado a rutas que influyen en el metabolismo de glucosa y lípidos, la inflamación y la función endotelial; puede asociarse con resistencia a la insulina y dislipidemia.
    ¿Qué es InnerBuddies y cómo ayuda con TMAO?
    InnerBuddies conecta la biología de TMAO con disparadores intestinales a monte, resalta patrones microbianos vinculados a la producción de TMA y apoya estrategias dietéticas y de microbioma personalizadas.
    ¿Qué síntomas pueden observarse con un riesgo elevado de TMAO?
    Los síntomas no son específicos; pueden incluir dolor en el pecho, menor tolerancia al ejercicio, hipertensión, incremento de glucosa o resistencia a la insulina, dislipidemia y cambios gastrointestinales como hinchazón.
    ¿Qué tan común es un TMAO elevado en la población general?
    La prevalencia varía según el estudio, método y dieta; no existe un umbral universal; TMAO elevado suele verse en personas con factores de riesgo cardiometabólicos.
    ¿Qué significa el eje intestino–hígado–corazón en este contexto?
    Describe cómo el TMA se produce en el intestino, cómo el hígado lo oxida a TMAO y qué señales downstream influyen en ácidos biliares, transporte de colesterol, función endotelial e inflamación.
    ¿Debería hacerme la prueba de TMAO?
    La prueba de TMAO puede considerarse para añadir contexto junto a otros factores de riesgo; los resultados deben interpretarse con un médico y no es un cribado de rutina.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -